However, SUP3 combined with Flt3L treatment did not demonstrate a synergistic antitumor effect in comparison to SUP3 or Flt3L treatment alone, either in the B16F10-Flt3L tumor model or after systemic administration of Flt3L (Fig. 7E and F). Here, FLT3LG is linked to neoplasm.